Key result
Cardiomyopathic mutations E40K and E54K alter Tpm1.7 properties, slowing F-actin sliding velocity ~3-fold versus wild-type.
Why the study?
Cardiomyopathy-causing mutations E40K and E54K in the TPM1 gene may be expressed in non-muscle cytoplasmic tropomyosin isoforms such as Tpm1.7, but their effects on Tpm1.7 properties had not been investigated.
Cardiomyopathic mutations in the TPM1 gene alter the properties of non-muscle Tpm isoforms, highlighting a potential novel molecular mechanism in cardiomyopathy pathogenesis.
Hypothesis-generating for non-muscle tropomyosin in cardiomyopathy; extends sarcomeric TPM1 studies but requires human validation.
Tropomyosins (Tpm) are the family of actin-binding proteins encoded by four genes in humans. Missense mutations in the TPM1 gene associated with cardiomyopathies have been studied in the sarcomeric isoform Tpm1.1. The cardiomyopathy-causing mutations E40K and E54K are located in exon 2b of the TPM1 gene and may be expressed in non-muscle cytoplasmic Tpm isoforms, including Tpm1.7, which is associated with early tissue development. In the present work, we investigate the effects of mutations E40K and E54K on the properties of Tpm1.7. The E40K and E54K mutations caused destabilization of the Tpm1.7 molecule at the N- and C-termini parts. Neither mutation affected the Tpm1.7 affinity for filamentous actin (F-actin). The bending stiffness of F-actin/Tpm1.7 E40K filaments was lower compared to F-actin/Tpm1.7 WT (wild-type). The interplay of Tpm1.7 and motor proteins was studied in an in vitro motility assay with skeletal myosin. Tpm1.7 WT reduced the sliding velocity of F-actin by half; the velocity of F-actin with Tpm1.7 E54K did not differ from that of bare F-actin; and Tpm1.7 E40K decreased the F-actin velocity by approximately threefold. While Tpm1.7 E40K did not affect the protective effect of Tpm1.7 against F-actin severing by cofilin-1, the E54K mutation enhanced protection against cofilin-1. Thus, cardiomyopathic mutations in the TPM1 gene can affect the properties of non-muscle Tpm isoforms, which indicates that this should be taken into account when studying the molecular mechanisms of the pathogenesis of these diseases.
No takes yet. Share an insight, caveat, or question.
Roman et al. (2026) studied Cardiomyopathies. E40K and E54K mutations in Tpm1.7 vs. Tpm1.7 WT (wild-type) was evaluated on Properties of Tpm1.7 (destabilization, affinity for F-actin, bending stiffness, sliding velocity). Cardiomyopathic mutations E40K and E54K altered Tpm1.7 properties, with E40K decreasing F-actin sliding velocity by approximately threefold compared to wild-type.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: